# ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Source: https://onco.cc/trials/nct06007729/  
OnCo record `nct06007729` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-20093 in head and neck squamous cell carcinoma, run by Hansoh BioMedical R&D Company, now recruiting.

## Summary

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06007729 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-12. Interventions recorded: HS-20093. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06007729
- Phase: 2
- Setting: ARTEMIS-006: A Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Administration of HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT06007729: https://clinicaltrials.gov/study/NCT06007729

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [HS-20093](https://onco.cc/drugs/hs-20093/)

---
JSON: https://onco.cc/api/v1/entities/nct06007729.json